Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and shelve its lead anti-cancer drug conjugate. The reprioritization is meant to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results